Avadel Pharmaceuticals plc is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right $(CVR)$ to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.